baber/WOPTO huggingface dataset:
Patent DE-69100769-T2 (DE)
Inventor: ARPESELLA GIORGIO
IPC: A61M60/569
Filed: 1991-03-12
Granted: 1994-04-07
Abstract: The device comprises, in a single functional combination, a first selectively contractible chamber (6) which is intended to be filled with a quantity of blood and is associated with a first valve (8) for admitting the quantity of blood to the first chamber and a second valve (9) for discharging it from it. A second selectively contractible chamber (5) can also be filled with a quantity of blood and has a flow member (12) arranged downstream of the discharge valve (9) of the first selectively contractible chamber (6) with reference to the direction of flow, for enabling the substantially unimpeded passage of blood out of and into the second selectively contractible chamber (5). An operator (24,25 and 26) causes the first (6) and second (5) chambers to contract in synchronism in a substantially pulsed manner. The device includes a common envelope (20) defining the first (6) and second (5) selectively contractible chambers and having a divider (21) which separate the first (6) and second (5) selectively contractible chambers.
Patent DE-69107215-T2 (DE)
Inventor: GLUCHOWSKI CHARLES
IPC: A61K31/498
Filed: 1991-07-22
Granted: 1995-05-24
Abstract: A compound selected from the group consisting of those having the formula:   <IMAGE>   and pharmaceutically acceptable acid addition salts thereof, wherein R1 and R4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R2s are each H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R3s are each H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo, provided that the R2s or the R3s are alkyl radicals; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8-positions of the quinoxaline nucleus; and R5, R6 and R7 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as alteration in the rate of fluid transport in the gastrointestinal tract, reduction in intraocular pressure, and increase in renal fluid flow.
Patent DE-69108247-T2 (DE)
Inventor: TILS HENRICUS
IPC: B03D1/14
Filed: 1991-06-11
Granted: 1995-11-09
Abstract: PCT No. PCT/NL91/00095 Sec. 371 Date Feb. 16, 1993 Sec. 102(e) Date Feb. 16, 1993 PCT Filed Jun. 11, 1991 PCT Pub. No. WO91/19572 PCT Pub. Date Dec. 26, 1991.A flotation cyclone for flotation of small particles of less than 30  mu m, comprising a cylinder (1) with an upper section, having a porous wall (4) and an extension (6) having a solid wall, said upper section being provided with a tangential inlet (2) and being covered with a lid, having a vortexfinder (10) as a foam outlet, and being surrounded by a gas chamber (3) having a gas inlet (3'), surrounding said porous wall (4), and being provided at the lower end of said porous wall (4) with a weir (5), while the extension (6) of said cylinder, having a solid wall, is provided at its lower end with a liquid as a blocking device.
Patent DE-69113485-T2 (DE)
Inventor: PIEPER CHRISTOPHER MARTIN
IPC: A61F13/15
Filed: 1991-01-02
Granted: 1996-03-28
Abstract: An absorbent article is described which comprises a substantially integral fibrous layer of hydrophilic fibers; and a quantity of superabsorbent particles integrally mixed among said fibers in a non-layered configuration, and arranged with weight percentages of said superabsorbent particles (with respect to a total weight of superabsorbent) nonuniformly distributed along a length dimension of said article with selected length-wise, superabsorbent-containing regions of said fibrous layer having higher percentages of superabsorbent than other length-wise, superabsorbent-containing regions. <IMAGE>
Patent DE-69119477-T2 (DE)
Inventor: YAMADA YOKO
IPC: C09K19/42
Filed: 1991-06-11
Granted: 1996-12-05
Abstract: A mesomorphic compound represented by the following formula (I): <CHEM> wherein R<1> and R<2> respectively denote a linear or branched alkyl group having 3 - 18 carbon atoms capable of including one or more methylene groups which can be replaced with at least one species of <CHEM>   <CHEM> with the proviso that -O- cannot directly be connected to -O-, and R<2> can also be halogen, -CN or -CF3; X denotes <CHEM>  -CH2O- or -OCH2; A denotes <CHEM>  or <CHEM> and m and n are respectively 0 or 1 with the proviso that m+n = 0 or 1. The mesomorphic compound is effective for providing a ferroelectric liquid crystal composition showing an improved low-temperature operation characteristic and a decreased temperature-dependence of response speed.
Patent DE-69206958-T2 (DE)
Inventor: DITTLO MICHEL
IPC: B21D37/08
Filed: 1992-10-30
Granted: 1996-05-23
Abstract: The subject of the present invention is a device for press-forming sheet materials, especially sheet-metal blanks (5), on a single-acting press, comprising, on the one hand, a pad (2) made of elastic material, especially an incompressible material, forming a punch (force plug) and housed in a retaining vessel (1) and, on the other hand, means for preforming and for final forming of the said sheet-metal blank (5). The preforming and final forming means are arranged in a die (6) comprising a frame (8), an upper peripheral blank holder (9) connected to the frame (8) via at least one elastic reaction, releasing (expanding) and retaining member and a die bottom (10) arranged in the upper peripheral blank holder (9), the said upper blank holder (9) and the said die bottom (10) being mounted so as to slide one in relation to the other and comprising means (13) for momentary connection between them. 
<IMAGE>
Patent DE-69214524-T2 (DE)
Inventor: MENTASTI PIETRO
IPC: G09F15/00
Filed: 1992-03-11
Granted: 1997-03-06
Abstract: Knockdown-elements framework for light signs, comprising a plurality of vertically arranged section bars (11) with quadrangular cross-section, one pair of edge section bars (1) with "L"-shaped cross-section, horizontally arranged in mutual opposite relation, a plurality of section bars with triangular cross-section (14), affixed, as pairs, on each vertical section bar (11), and with a continuous "U"-shaped seat (14a) at 45<o> relatively to the relevant vertical section bar, one pair of horizontally arranged section bars (17) with box-like cross-section, provided with a flange (17b) designed to support the sign, a quadrangular hollow designed to support the flexible sheet stretching device, a continuous, quadrangular seat (17a) at 45<o> opposite to the corresponding seat of said triangular section bars, and a groove-like seat (30) designed to slidingly support light reflective plates, a plurality of section bars (29) also provided with groove-like seats at 45<o> in order to slidingly support the other side of said plates, a plurality of section bars (16) with quadrangular cross-section arranged at 45<o> relatively to the vertical section bars inserted inside the seats provided in the triangular section bars and in the section bars with box-like cross-section, and plate-shaped covering elements (8) installed both above and under the structure. <IMAGE>
Patent DE-69217042-T2 (DE)
Inventor: LAEHDEMAEKI HEIMO
IPC: H04B3/23
Filed: 1992-10-28
Granted: 1997-06-19
Abstract: The operation of an echo canceller (4A to 4D) is controlled by a call control (2) of a telephone exchange over an internal control bus (3, 5) of the telephone exchange. The exchange then attends to the necessary signalling and the echo canceller does not need to know how the associated signalling is routed in the telephone network.
Patent DE-69217350-T2 (DE)
Inventor: CABOCHE JEAN-JACQUES
IPC: A23L27/30
Filed: 1992-12-28
Granted: 1997-07-24
Abstract: Low-cariogenic hydrogenated starch hydrolysate, characterised in that it has a sorbitol content of 0.1 to 19 % by weight, a maltitol content of 35 to 87 % by weight, a content of 1 to 17 % by weight of polysaccharides which are not hydrolysable by amyloglucosidase in an F test, the remainder to 100 % consisting of hydrogenated oligo- or polysaccharides. This hydrolysate can be employed as sweetening agent or as texture agent in products intended to be ingested by humans or animals, especially in sweets and chewing gums, as well as in alimentary or pharmaceutical syrups and elixirs.
Patent DE-69217689-T2 (DE)
Inventor: DAVIS ROBERT
IPC: B23B31/00
Filed: 1992-04-07
Granted: 1997-07-03
Abstract: A surgical bone reamer 10 includes a rotatable, elongated shank 12 having a proximal end 14, a distal end 16 and a longitudinal axis, and a reaming head 18 mounted on the distal end 16. A plurality of equally spaced walls 34 are radially disposed on the reaming head around the longitudinal axis, and tip edges 40 for penetrating bone are defined on the radial walls 34 to be disposed angularly with the longitudinal axis. Reaming edges 42 joined to the tip edges 40 extend longitudinally from the tip edges 40 in the proximal direction parallel to and an equal radial distance from the longitudinal axis for reaming a cylindrical tunnel when the reaming head 18 is rotated in bone. Tapered flutes 48 disposed angularly between the tip edges 40 and the radial walls 34 permit bone to be evacuated through the reaming head 18 when forming a tunnel in bone. <IMAGE>
Patent DE-69219588-T2 (DE)
Inventor: LEE SUNG
IPC: C07F9/6533
Filed: 1992-02-19
Granted: 1998-01-02
Abstract: A new class of phosphines in which the phosphorous atom is bonded directly to the carbon of an oxazinone:   <IMAGE>   In addition to their anti-inflammatory activity, these phosphines are useful as intermediates in producing compounds where the phosphine is replaced by a benzylidine, compounds which have also been proven useful in the treatment of inflammation and other conditions associated with arthritis.
Patent DE-69220442-T2 (DE)
Inventor: MATTSSON CHRISTER
IPC: A61K31/727
Filed: 1992-04-14
Granted: 1998-01-29
Abstract: The invention relates to new heparin derivatives from bovine or porcine heparin which have a molecular weight equal to or larger than the standard heparin, show a sulfur content which is equal to or higher than that of the starting heparin or at least 13% w/w, have an anticoagulant activity in the anti-FXa assay of less than 10% of the standard heparin it was made from, show a ratio of APTT activity over anti-FXa activity of 3-35, show a reduced prolongation of bleeding time compared to the standard heparin it was made from as measured in the rat tail after i.v. administration and show enhancement of the rate of development of coronary collaterals in dogs equal to or better than clinically used heparin. The invention also relates to processes for preparation of the new bovine and porcine heparin derivatives. The use of this product for the manufacturing of a medicament for treatment of ischemic heart disease and related vascular disorders and for the enhancement of the rate of development of coronary collateral perfusion is disclosed.
Patent DE-69230971-T2 (DE)
Inventor: DRURY LEE
IPC: H02G5/04
Filed: 1992-08-05
Granted: 2000-12-07
Abstract: A flexible conductive track (1), comprises a flexible insulative plastics housing (2) of constant cross section. This housing is substantially rectangular in shape with three recesses (3) open to one side of the housing. A conductor (4) in the form of a copper wire is held in the bottom of each recess. Affixed to the wire (4) along the whole length of the wire is a conductive blade (5) which is conductively bonded to the wire (4) to form a double spring blade contact (5). A recess (16) is located on the other side of the housing (2). When the track (1) is bent laterally the recess (16 and 3) collapse to assist in the bending.
Patent DE-69232782-T2 (DE)
Inventor: LINDHOLM LEIF
IPC: C12N15/87
Filed: 1992-10-28
Granted: 2003-02-20
Abstract: PCT No. PCT/SE92/00745 Sec. 371 Date Jun. 17, 1994 Sec. 102(e) Date Jun. 17, 1994 PCT Filed Oct. 28, 1992 PCT Pub. No. WO93/09221 PCT Pub. Date May 13, 1993A complex between a virus the cell binding receptor of which has been inactivated and an antibody, said antibody having the ability to interact with a specific antigen on the surface of a mammalian cell different from the cellular structure which would otherwise mediate binding of the virus to the cell surface and which antigen has the ability to mediate entrance of a virus vector or infectious virus into mammalian cells.
Patent DE-69233271-T2 (DE)
Inventor: RUBINSTEIN ARYE
IPC: A61K39/385
Filed: 1992-04-02
Granted: 2004-09-09
Abstract: This invention relates to conjugates of peptides with amino acid sequences similar to the gp120 PND of HIV and carriers which enhance immunogenicity, such conjugates to be used in vaccines for the treatment and transmission prevention of HIV. After vaccination with the conjugates, antibody-containing fluid is extracted from individuals and assessed in an antigen-limited ELISA which contains a thimerosal-containing diluent and selects for high affinity/avidity neutralizing and/or protective HIV-specific antibodies. The conjugates which have induced the production of such antibodies are useful in the treatment and transmission prevention of HIV.
Patent DE-69307584-T2 (DE)
Inventor: KEMPEN HENRICUS GERARDUS MARIA
IPC: B05C9/02
Filed: 1993-04-21
Granted: 1997-05-15
Abstract: A device for applying a coating of an adhesive substance to an endless belt (2, 12) forming part of a screen printing machine is described. The device comprises a trough (3, 13) and pumping means (6, 16) for filling the trough (3, 13) with a stock (4, 14) of an adhesive substance to such a level that the meniscus thereof comes into contact with the endless belt (2, 12). The excess adhesive substance is removed from the belt using doctor means (5, 15). The device can also comprise pressure setting means such as a pressure bellows (51), for setting the pressure at which the doctor means (45) rest against the surface of the endless belt (42). <IMAGE>
Patent DE-69314497-T2 (DE)
Inventor: HANSON GUNNAR
IPC: C07D295/12
Filed: 1993-08-13
Granted: 1998-03-05
Abstract: Compounds characterized generally as oxazopinyl-terminated alkylamino ethynyl alanine amino diol derivatives are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are those of Formula I    <IMAGE>  (I)  wherein A is selected from CO and SO2; wherein X is selected from oxygen atom and methylene; wherein B is an oxazopinyl group; wherein R1 is selected from hydrido, methyl, ethyl, isopropyl and n-propyl; wherein R2 is phenylmethyl; wherein each of R3 and R5 is hydrido; wherein R4 is selected from -(CH2)q-C 3BOND C-V wherein V is selected from hydrido and methyl; wherein R6 is cyclohexylmethyl; wherein R7 is selected from isobutyl, cyclopropyl and cyclopropylmethyl; wherein q is a number selected from zero through three, inclusive; and wherein n is a number selected from zero through three, inclusive; or a pharmaceutically-acceptable salt thereof.
Patent DE-69315168-T2 (DE)
Inventor: CUNNANE III FRANCIS J
IPC: D21F7/08
Filed: 1993-09-28
Granted: 1998-03-12
Abstract: Hollow synthetic monofilament yarns (18) are used in the construction of a base fabric (21) for a papermakers wet felt (20). The synthetic hollow monofilament yarns (18) have selected interior void, compressibility and resiliency characteristics and are interwoven with other yarns (1-16) to form a woven base fabric with the hollow monofilament yarns predominating, on at least the paper carrying side of the base fabric. The weaving and finishing of the base fabric (21) results in the hollow monofilament yarns (18) retaining a substantially unflattened cross-section. Accordingly, substantially unflattened portions of the hollow monofilament yarns (18) predominate the paper carrying side of the base fabric thereby providing a cushioning surface which is compressibly resilient to assist in the dewatering of the aqueous paper web as it is transported through a press nip during the manufacture of the paper. Hollow nylon monofilament yarns having approximately 18% internal core void have been found to exhibit the desired compressibility and resiliency characteristics. Preferably a fibrous batt is needled to the base fabric to finish the wet press felt. <IMAGE>
Patent DE-69316388-T2 (DE)
Inventor: POTTER ELLEN
IPC: C12P21/08
Filed: 1993-10-25
Granted: 1998-08-13
Abstract: A Corticotropin Releasing Factor-binding protein (CRF-BP) is isolated and purified sufficient to provide AA sequence data from which the DNA is obtained, which is then used to produce the protein recombinantly. The CRF-BP is useful for modulating the biological activity of CRF, such as reducing the high ACTH levels in mammals caused by excess CRF. The CRF-BP or fragments thereof and/or antibodies to the proteins may be employed in diagnostic assays to determine the levels of CRF, CRF-BP and the ratio of CRF/CRF-BP in a vascular fluid sample. The DNA or subsequence thereof can be used as probes for genetic material in certain assays. The anti-CRF-BP antibodies are also useful to purify the CRF-BP protein and to modulate the biological effect of CRF-BPs proteins.
Patent DE-69317025-T2 (DE)
Inventor: TESTART GERARD
IPC: E01B7/12
Filed: 1993-08-31
Granted: 1998-09-03
Abstract: The present invention relates to an installation of the movable point in the crossing piece incorporated in long welded rails and a method for producing such an installation. The installation, characterised in that the linkage between the movable point (1) and the element (2'') of the crossing piece constituted by two rails (3 and 4) is made by essentially mechanical assembly. The invention is more particularly applicable in the field of constructing railway track equipment, in particular crossings (frogs, points). <IMAGE>
Patent DE-69329414-T2 (DE)
Inventor: OSAMU SHIMOYOSHI
IPC: G10L19/02
Filed: 1993-11-25
Granted: 2001-01-18
Abstract: An apparatus for orthogonally transforming a digital information signal is disclosed to provide an orthogonally-transformed signal The digital information signal represents a physical quantity in a first domain and the orthogonally transformed signal represents the physical quantity in a second domain, orthogonal to the first domain. The apparatus comprises orthogonal transform means (103-106) for orthogonally transforming the digital information signal in blocks, the orthogonal transform means (103-106) including plural, serially-arranged, processing stages (103-105), each processing stage (103-105) receiving a signal block from an immediately preceding processing stage for processing, a first one of the plural processing stages receiving each block of the digital information signal as a signal block for processing. The apparatus further comprises determining means (107-109) for determining a scale down amount for the signal block received by one of the plural processing stages (103-105) and scale down means (120-130) for scaling down the signal block received by the one of the plural processing stages by the scale down amount. <IMAGE>
Patent DE-69329735-T2 (DE)
Inventor: JONDAL MIKAEL
IPC: C07K9/00
Filed: 1993-04-23
Granted: 2001-08-02
Abstract: The present invention relates to a novel class of immunologically active compounds, to processes for their production and to their use in therapy. In particular, the invention provides immunogenic peptide-carbohydrate conjugates useful for generating T cell immunity against tumor-associated carbohydrate structures, or against carbohydrate structures expressed on infectious agents and/or infected host cells. The immunogenic conjugate comprises a peptide component capable of binding a MHC class I molecule and a carbohydrate component having the same immunogenic characteristics of the carbohydrate structure on the tumor cell, infectious agent or the infected cells.
Patent DE-69411557-T2 (DE)
Inventor: RASMUSSEN TORBEN
IPC: B29C41/38
Filed: 1994-04-13
Granted: 1998-10-29
Abstract: The mutually associated moulding tools, such as a suction mould and an associated pressing-and-depositing mould, neither of which are shown, comprise a baseplate (1) with a modularly divided, rectangular area (2) provided with perforations (3), on which area (2) it is possible to secure, e.g. by means of screws, a number of closely adjacent modular mould parts (A,B) with a rectangular outline, each of the modular mould parts (A,B) serving to produce an article (C,D,E) to be separated from the pulp-material shell having been produced in a subsequent operation. With this arrangement, it is possible to keep the cost of manufacturing the moulding tools and the time required for re-arranging them at such low levels, that even small series of articles (C,D,E) may be manufactured profitably.
Patent DE-69418495-T2 (DE)
Inventor: ALLAF KARIM
IPC: A23L19/00
Filed: 1994-08-03
Granted: 1999-12-16
Abstract: PCT No. PCT/FR94/00975 Sec. 371 Date Jul. 12, 1996 Sec. 102(e) Date Jul. 12, 1996 PCT Filed Aug. 3, 1994 PCT Pub. No. WO95/04466 PCT Pub. Date Feb. 16, 1995Materials, for example, plant-based food products, are subjected to heat and pressure in a processing enclosure, wherein the pressure is greater than the pressure of the atmosphere. The heated, pressurized materials are then subjected to a pressure-reduction phase during which the pressure in the processing enclosure is reduced at a rate greater than 500 millibars per second and by an amplitude greater than 1 bar. The rapid pressure-reduction phase of the invention contributes to the production of processed materials having a slightly spongy structure that is due to the presence of micro-cavities that promote the recapture of subsequent moisture.
Patent DE-69431041-T2 (DE)
Inventor: FUH GERMAINE
IPC: C07K14/61
Filed: 1994-02-09
Granted: 2003-02-06
Abstract: We have discovered that growth hormones form ternary complexes with their receptors in which site 1 on the hormone first binds to one molecule of receptor and then hormone site 2 then binds to another molecule of receptor, thereby producing a 1:2 complex. We believe this phenomenon is shared by other ligands having similar conformational structure. Assays based on this phenomenon are useful for identifying ligand agonists and antagonists. Sites 1 and 2 are structurally identified to facilitate generation of amino acid sequence variants of ternary complex-forming ligands. Novel variants of growth hormone, prolactin placental lactogen and other related ligands are provided. As a result of our studies with the ternary complex we have determined that selected antibodies to the receptor for these ligands are capable of acting as ligand agonists or antagonists. Novel growth hormones and novel uses for anti-growth hormone receptor antibodies are described. Methods for inhibiting the growth of breast cancer cells are also described.
Patent DE-69502183-T2 (DE)
Inventor: BENARROUCH JACQUES
IPC: B65D75/14
Filed: 1995-02-15
Granted: 1998-08-13
Abstract: PCT No. PCT/FR95/00181 Sec. 371 Date Nov. 12, 1996 Sec. 102(e) Date Nov. 12, 1996 PCT Filed Feb. 15, 1995 PCT Pub. No. WO95/21781 PCT Pub. Date Aug. 17, 1995A package for a food product such as a cylindrical sandwich includes an elongate central strip having a plurality of fold lines defining a series of panels. A central panel of the series includes a central flap connected at each side edge, and other closure flaps are connected to at least some of the other panels. The panels are folded with respect to each other so that the endmost panels are positioned to define a polygonal cross-section for the package. The closure flaps and central flaps are folded to close the package. An outer portion of each central flap is free from the remaining closure flaps to permit outward folding of the panels for access to the food product. Several alternative embodiments are disclosed.